Prism Johnson: Q1 FY27 Consolidated EBITDA Surges 26.6% to ₹221 Crore

Prism Johnson Limited reported a strong performance in Q1 FY27, with consolidated EBITDA increasing by 26.6% YoY to ₹221 crore. This growth was driven by robust execution across its business segments, particularly H&R Johnson and Prism RMC, and resilience in Prism Cement. The company also saw an improvement in ROCE to 21.8%, reflecting disciplined capital allocation and stronger operating performance.

Prism Johnson Reports Strong Q1 FY27 Performance

Prism Johnson Limited delivered one of its strongest quarterly performances in Q1 FY27, achieving a consolidated EBITDA of ₹221 crore, marking a significant increase of 26.6% year-on-year. This impressive growth was fueled by robust execution in the H&R Johnson and Prism RMC segments, while Prism Cement demonstrated resilience amidst a softer market.

Key Financial Highlights

The company’s focus on disciplined capital allocation and operational efficiencies contributed to an improved ROCE of 21.8% for the quarter. This performance was achieved despite facing external headwinds such as elevated fuel costs and raw material inflation, and a competitive pricing environment in the cement industry. The completed divestment of Raheja QBE General Insurance is expected to sharpen the company’s focus on its core building materials business and accelerate deleveraging.

Segment Performance

In Q1 FY27, consolidated revenue stood at ₹1,844 crore, with Prism Cement contributing 49%, H&R Johnson 28%, and Prism RMC 23%. The EBITDA margin for the quarter was 12.0%, a notable improvement driven by operational leverage and cost management.

Balance Sheet Strengthening

The company continues to strengthen its balance sheet through sustained debt reduction and non-core asset monetization. Net debt as of June 30, 2026, stood at ₹577 crore. The divestment of Raheja QBE General Insurance for ₹325.87 crore, completed on July 1, 2026, is anticipated to further enhance the balance sheet and sharpen the company’s strategic focus.

Source: BSE

Previous Article

Cera Sanitaryware: Q1 FY27 Unaudited Results Show ₹4,531 Crore Profit

Next Article

Alivus Life Sciences: Q1 FY27 Revenue Grows 6.4% to ₹640 Crore